Biolexis Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small-molecule drug candidates using its proprietary MolecuLern AI-enabled drug discovery process. The company focuses on small molecules targeting cancers, immune-mediated, neurodegenerative, autoimmune, metabolic, and inflammatory diseases. Its MolecuLern process targets any class of protein to identify novel chemical entities with drug-like characteristics and wet-lab validation, aiming to shorten discovery timelines from years to months. Biolexis reports 40 active programs in discovery and 10 pipeline programs in IND-enabling stages. Led by CEO David Bearss and based in American Fork, Utah, the company intends to use the new funds to expand operations and accelerate clinical development of key candidates. The firm raised $10M in a Series A financing led by Clarke Capital.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2023